LEGACY: A Multicenter Study Confirming TheraSphere™ as a Neoadjuvant or Standalone Therapy in Treating HCC
By
Boston Scientific
FEATURING
Vivian Bishay
By
Boston Scientific
FEATURING
Vivian Bishay
The LEGACY study is a multicenter, retrospective study demonstrating reproducible treatment outcomes across multiple centers and confirms published outcomes previously published in single center studies. This presentation provides background on the use of Y-90 glass microsphere to treat HCC, discusses results of the LEGACY study and recently published studies using Y-90 glass microspheres.
Comments 0
Login to view comments.
Click here to Login
Product Workshop LEGACY: A Multicenter Study Confirming TheraSphere as a Neoadjuvant or Standalone Therapy in Treating HCC
Thumbs Up
- October 19, 2020
